Dirk Heerwegh

Beerse, VLG, Belgium

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 22 publications

Plain Language Summary of Publication: Design of the Phase 3 FREESIA-1 and FREESIA-3 Trials of Nipocalimab in Fetal and Neonatal Alloimmune Thrombocytopenia.

Plain Language Summary of Publication: Design of the Phase 3 FREESIA-1 and FREESIA-3 Trials of Nipocalimab in Fetal and Neonatal Alloimmune Thrombocytopenia.

Journal: American journal of perinatology
Published: December 29, 2025

Design of a Phase 3, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study of Nipocalimab in Pregnancies at Risk for Fetal and Neonatal Alloimmune Thrombocytopenia.

Design of a Phase 3, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study of Nipocalimab in Pregnancies at Risk for Fetal and Neonatal Alloimmune Thrombocytopenia.

Journal: American journal of perinatology
Published: July 28, 2025

Pre- and post-Ad26.COV2·S booster dose antibody levels predict COVID-19 disease risk.

Pre- and post-Ad26.COV2·S booster dose antibody levels predict COVID-19 disease risk.

Journal: Vaccine
Published: April 02, 2024

Safety, reactogenicity, and immunogenicity of Ad26.COV2.S as homologous or heterologous COVID-19 booster vaccination: Results of a randomized, double-blind, phase 2 trial.

Safety, reactogenicity, and immunogenicity of Ad26.COV2.S as homologous or heterologous COVID-19 booster vaccination: Results of a randomized, double-blind, phase 2 trial.

Journal: Vaccine
Published: December 04, 2023

Measuring respiratory syncytial virus infection severity in hospitalized children using the Pediatric Respiratory Syncytial Virus Electronic Severity and Outcome Rating System (PRESORS).

Measuring respiratory syncytial virus infection severity in hospitalized children using the Pediatric Respiratory Syncytial Virus Electronic Severity and Outcome Rating System (PRESORS).

Journal: Influenza and other respiratory viruses
Published: June 22, 2022

Non-human primate to human immunobridging demonstrates a protective effect of Ad26.ZEBOV, MVA-BN-Filo vaccine against Ebola.

Non-human primate to human immunobridging demonstrates a protective effect of Ad26.ZEBOV, MVA-BN-Filo vaccine against Ebola.

Journal: NPJ vaccines
Published: March 25, 2022

Durable antibody responses elicited by 1 dose of Ad26.COV2.S and substantial increase after boosting: 2 randomized clinical trials.

Durable antibody responses elicited by 1 dose of Ad26.COV2.S and substantial increase after boosting: 2 randomized clinical trials.

Journal: Vaccine
Published: February 01, 2022

Impact of Preexisting Anti-Adenovirus 26 Humoral Immunity on Immunogenicity of the Ad26.COV2.S Coronavirus Disease 2019 Vaccine.

Impact of Preexisting Anti-Adenovirus 26 Humoral Immunity on Immunogenicity of the Ad26.COV2.S Coronavirus Disease 2019 Vaccine.

Journal: The Journal of infectious diseases
Published: December 10, 2021

Passive transfer of Ad26.COV2.S-elicited IgG from humans attenuates SARS-CoV-2 disease in hamsters.

Passive transfer of Ad26.COV2.S-elicited IgG from humans attenuates SARS-CoV-2 disease in hamsters.

Journal: NPJ vaccines
Published: October 04, 2021

Durable Humoral and Cellular Immune Responses Following Ad26.COV2.S Vaccination for COVID-19.

Durable Humoral and Cellular Immune Responses Following Ad26.COV2.S Vaccination for COVID-19.

Journal: medRxiv : the preprint server for health sciences
Published: July 16, 2021

Durable Humoral and Cellular Immune Responses 8 Months after Ad26.COV2.S Vaccination.

Durable Humoral and Cellular Immune Responses 8 Months after Ad26.COV2.S Vaccination.

Journal: The New England journal of medicine
Published: July 14, 2021

Safety and immunogenicity of 2-dose heterologous Ad26.ZEBOV, MVA-BN-Filo Ebola vaccination in children and adolescents in Africa: A randomised, placebo-controlled, multicentre Phase II clinical trial.

Safety and immunogenicity of 2-dose heterologous Ad26.ZEBOV, MVA-BN-Filo Ebola vaccination in children and adolescents in Africa: A randomised, placebo-controlled, multicentre Phase II clinical trial.

Journal: PLoS medicine
Published: May 20, 2021
Showing 1-12 of 22

Last Updated: 09/26/2026